208 related articles for article (PubMed ID: 22844475)
1. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma.
Lehtinen J; Raki M; Bergström KA; Uutela P; Lehtinen K; Hiltunen A; Pikkarainen J; Liang H; Pitkänen S; Määttä AM; Ketola RA; Yliperttula M; Wirth T; Urtti A
PLoS One; 2012; 7(7):e41410. PubMed ID: 22844475
[TBL] [Abstract][Full Text] [Related]
2. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
3. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Dekker LC; Van Hoesel QG; Crommelin DJ; Storm G
Br J Cancer; 1996 Oct; 74(7):1023-9. PubMed ID: 8855969
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
5. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model.
Zavaleta CL; Phillips WT; Soundararajan A; Goins BA
Int J Pharm; 2007 Jun; 337(1-2):316-28. PubMed ID: 17276633
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
7. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
8. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
Huhtala T; Laakkonen P; Sallinen H; Ylä-Herttuala S; Närvänen A
Nucl Med Biol; 2010 Nov; 37(8):957-64. PubMed ID: 21055627
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A; Koren E; Koshkaryev A; Torchilin VP
Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
[TBL] [Abstract][Full Text] [Related]
10. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
11. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer.
Mir Y; Elrington SA; Hasan T
Nanomedicine; 2013 Oct; 9(7):1114-22. PubMed ID: 23485748
[TBL] [Abstract][Full Text] [Related]
12. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
14. Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging.
Jeong HY; Kang SJ; Kim MW; Jeong IH; Choi MJ; Jung C; Song IH; Lee TS; Park YS
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339090
[TBL] [Abstract][Full Text] [Related]
15. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and antitumor effect of Cetuximab-targeted lentivirus.
Huhtala T; Kaikkonen MU; Lesch HP; Viitala S; Ylä-Herttuala S; Närvänen A
Nucl Med Biol; 2014 Jan; 41(1):77-83. PubMed ID: 24267054
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
18. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection.
Petrilli R; Eloy JO; Saggioro FP; Chesca DL; de Souza MC; Dias MVS; daSilva LLP; Lee RJ; Lopez RFV
J Control Release; 2018 Aug; 283():151-162. PubMed ID: 29864476
[TBL] [Abstract][Full Text] [Related]
19. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
20. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.
Wöll S; Dickgiesser S; Rasche N; Schiller S; Scherließ R
Eur J Pharm Biopharm; 2019 Mar; 136():203-212. PubMed ID: 30677497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
